Log In
Print
BCIQ
Print
Print this Print this
 

VR040

  Manage Alerts
Collapse Summary General Information
Company Vectura Group plc
DescriptionInhaled apomorphine
Molecular Target Dopamine receptor
Mechanism of ActionDopamine receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat "off" episodes in patients with fluctuating Parkinson's disease (PD); Treat idiopathic Parkinson's disease (PD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today